Fmoc-L-phenylalanine (Fmoc-Phe-OH; CAS 35661-40-6; molecular weight 387.43 g/mol) is incorporated as an N-α-protected monomer during stepwise solid-phase peptide synthesis (SPPS) on polypropylene or polytetrafluoroethylene reaction vessels in automated synthesizers with nitrogen-assisted vortex mixing. The process relies on repeated cycles of Fmoc deprotection and amino acid coupling; residual free amino groups after each coupling are assessed by Kaiser test or bromophenol blue indicator, and a positive reading triggers an immediate recoupling with 2 equivalents of Fmoc-Phe-OH activated by the same chemistry. In a representative Fmoc/tBu protocol on 100–200 mesh aminomethyl polystyrene cross-linked with 1% divinylbenzene, the monomer is activated with 2.9 equivalents of HBTU and 2.9 equivalents of 1-hydroxybenzotriazole or with 2.9 equivalents of HATU and 6 equivalents of N,N-diisopropylethylamine in N,N-dimethylformamide relative to resin-bound free amine; the Fmoc-Phe-OH molar excess is maintained at 3.0 equivalents for a resin substitution of 0.40–0.60 mmol/g. Coupling proceeds for 45–60 minutes at 20–25°C under continuous nitrogen bubbling. Deprotection is carried out with 20% v/v piperidine in DMF for two cycles of 5 minutes and one cycle of 10 minutes; the UV absorbance of the released dibenzofulvene-piperidine adduct at 301 nm is integrated to calculate coupling yield. Solvent quality is controlled before use: DMF water content is kept below 0.01% by Karl Fischer titration, and peroxide-forming solvents are stabilized with butylated hydroxytoluene if used in resin conditioning. The peptide is cleaved with trifluoroacetic acid/triisopropylsilane/water at 95:2.5:2.5 v/v/v for 2–3 hours and precipitated in cold methyl tert-butyl ether. Manufacturing compliance follows ICH Q7 for API production, 21 CFR 210/211 for cGMP batch release, USP <467> for residual DMF and dichloromethane, and USP <621> for HPLC purity; piperidine content in the final peptide is controlled by liquid chromatography with a limit derived from ICH Q3C. Final products include linear, cyclic, and N-methylated peptide drug substances containing internal or C-terminal phenylalanine residues, prepared at scales from gram to multi-kilogram in campaign mode.

What Limits Enantiomeric Purity During Fmoc-Phe-OH Loading onto 2-Chlorotrityl Chloride Resin?

Loading of Fmoc-L-phenylalanine onto 2-chlorotrityl chloride resin for C-terminal phenylalanine peptides is performed in anhydrous dichloromethane with 1.2–1.5 equivalents of Fmoc-Phe-OH and 3.0–4.0 equivalents of diisopropylethylamine relative to resin chloride. The substitution target is kept between 0.40 mmol/g and 0.75 mmol/g because higher loading increases inter-chain steric hindrance and weakens the ninhydrin colorimetric response. Enantiomeric purity is the critical process variable: chloride displacement generates a benzylic carbocation-like intermediate that can promote racemization when the unprotected amino acid carboxylate is over-activated or when base concentration is too high. Peer-reviewed data for the racemization rate of Fmoc-Phe-OH on 2-chlorotrityl chloride in anhydrous dichloromethane is limited; therefore, release relies on chiral HPLC rather than kinetic prediction. Batches manufactured on a 100 mmol scale in a 2 L glass reactor with overhead stirring and a nitrogen inlet have shown acceptable chiral purity above 99.0% by chiral HPLC when diisopropylethylamine is limited to 4.0 equivalents and the reaction is quenched with methanol after 60 minutes; extension beyond 120 minutes is avoided because the D-phenylalanine content rises. After quenching, the resin is washed with DMF, dichloromethane, and methanol and dried under vacuum at 25°C for 12 hours; residual chloride is capped with 30% methanol in dichloromethane because unreacted chlorotrityl groups can alkylate the next incoming amine. Quality limits for the loaded resin include a substitution level determined by UV spectrophotometric cleavage with piperidine and residual chloride below 0.05 mmol/g by argentometric titration. The loaded Fmoc-Phe-O-2-chlorotrityl resin is then transferred to automated peptide synthesizers; compliance rests on ICH Q7 for resin handling, USP <621> for HPLC purity, and EP 2.2.29 for enantiomeric purity. This route is preferred over Wang resin when diketopiperazine formation at the dipeptide stage is a known threat for C-terminal phenylalanine peptides.

At pH values above 8.0, Fmoc-L-phenylalanine forms a clear aqueous solution as the carboxylate salt; controlled acidification below pH 5.0 triggers β-sheet and π-stacking self-assembly into a fibrillar hydrogel network. The pH-switch route uses deionized water, 1.0 equivalent of sodium hydroxide, and glucono-δ-lactone as a slow acidifier; the rate of acidification determines fibril length distribution and final storage modulus. Reported gelation concentrations for Fmoc-L-phenylalanine in phosphate-buffered saline fall within 0.1% w/v to 0.5% w/v, though published data for this specific configuration with added serum proteins is limited; gel formation is considered confirmed when dynamic oscillatory rheology on a 40 mm cone-plate geometry at 1 Hz and 0.1% strain shows G′ exceeding G″ by at least one order of magnitude. The gelation vessel is kept at 25°C for 18–24 hours to avoid thermal gradients that produce anisotropic domains. Because the material is used as a scaffold for mammalian cell culture, incoming Fmoc-Phe-OH is tested for bacterial endotoxin according to USP <85> with an acceptance criterion below 0.5 EU/mL in the final hydrated scaffold, and the hydrogel is prepared under a Class II biological safety cabinet using sterile-filtered buffers. The material is physically crosslinked, so it undergoes shear-thinning and reversible recovery at low strain; this behavior is characterized by step-strain rheology with a recovery interval of 120 seconds, and loss of G′ beyond 15% of the initial value after three cycles is treated as batch failure. Final products are fibrillar hydrogels used as cell culture matrices, peptide-based drug release reservoirs, and printable inks for extrusion-based 3D bioprinting; cytotoxic potential is evaluated with ISO 10993-5 in vitro cytotoxicity methods when the scaffold contacts primary human fibroblasts or stem cell lines.

When Fmoc-L-Phenylalanine Replaces Boc-L-Phenylalanine in Solution-Phase Peptide Fragment Manufacturing

Solution-phase synthesis of protected phenylalanine peptide fragments is selected when fragment condensation offers better isolation and scale control than stepwise SPPS. In mixed anhydride activation, Fmoc-Phe-OH is dissolved in anhydrous tetrahydrofuran or ethyl acetate and cooled to −15°C to −20°C under nitrogen; 1.05 equivalents of isobutyl chloroformate and 1.1 equivalents of N-methylmorpholine are added over 10 minutes, and the resulting mixed anhydride is coupled to an amino acid tert-butyl ester or peptide fragment containing a free amino group. The Fmoc protecting group is stable during acidic workup with 10% citric acid and during crystallization from ethyl acetate/n-heptane, but it is incompatible with secondary amines because β-elimination releases dibenzofulvene and regenerates the free amine; therefore, piperidine is excluded from any upstream storage vessel and tertiary amines are used for carboxylate activation. In process development batches, coupling yields above 90% are achieved when the amine component is added as a 0.2 M solution in tetrahydrofuran and the reaction is warmed from −15°C to 2–8°C over 60 minutes; precipitated N-methylmorpholine hydrochloride is removed by filtration through a 0.45 μm polytetrafluoroethylene membrane. The protected fragment is washed with 5% sodium bicarbonate and 10% sodium chloride, dried over sodium sulfate, and concentrated below 35°C to avoid premature Fmoc cleavage. Residual tetrahydrofuran in the isolated fragment is controlled by headspace gas chromatography according to USP <467>, water content by Karl Fischer titration according to USP <921>, and purity by reverse-phase HPLC according to USP <621>; the final fragment must also meet ICH Q3D elemental impurity limits for palladium, nickel, and copper if hydrogenation or transition-metal catalysis is used elsewhere in the route. Final products include protected dipeptide and tripeptide intermediates such as Fmoc-Phe-Gly-OtBu or Fmoc-Phe-Leu-OMe, which are then deprotected and coupled into larger peptide drug substances under cGMP conditions. Monitoring is by thin-layer chromatography with cerium molybdate stain and by LC-MS with electrospray ionization; any batch with unidentified single impurity above 0.5 area% by HPLC is re-purified by silica gel column chromatography or preparative HPLC before release.

Incoming Quality Control, Storage, and Capping Strategy in Automated Peptide Synthesizers

In the incoming quality control laboratory, Fmoc-L-phenylalanine lots are stored at 2–8°C in airtight amber glass containers with desiccant packs, and each container is equilibrated to ambient temperature before opening to prevent condensation on the powder. Water content is a critical attribute because residual moisture in the monomer can hydrolyze the Fmoc group during extended storage and depress coupling efficiency; the acceptance limit is set at ≤0.5% water by Karl Fischer coulometry according to USP <921>. HPLC purity by gradient reverse-phase liquid chromatography according to USP <621> is set at ≥99.0 area%, and enantiomeric purity is set at ≤0.5% Fmoc-D-phenylalanine by chiral HPLC according to EP 2.2.29. Residual solvents are tested against ICH Q3C using headspace gas chromatography; the supplier certificate of analysis must include identity by infrared spectroscopy, specific optical rotation, and a visual appearance check for off-white to white powder. In automated SPPS, capping of unreacted free amines after the phenylalanine coupling step is performed with 0.5 M acetic anhydride and 0.3 M 2,6-lutidine in DMF for 10 minutes at 20–25°C; this step prevents deletion peptide sequences from participating in subsequent elongation cycles. The capping reagent ratio is calibrated to the resin substitution level, and repeated capping beyond two cycles is avoided because acetylation of the resin-bound phenylalanine amino group can occur if Fmoc protection is inadvertently lost. The following incoming quality control matrix summarizes release parameters and associated standards.

After the release gate, the powder is transferred to the synthesis suite under a dry nitrogen purge. If water content exceeds 0.5% w/w, the powder is dried under vacuum at 25°C over phosphorus pentoxide for 12 hours and retested; material with HPLC purity below 99.0 area% is rejected for cGMP campaigns and may be re-purified by flash column chromatography only for non-GMP process development. Because Fmoc-L-phenylalanine contains a π-conjugated fluorenylmethyl group, direct sunlight exposure is avoided; handling under ambient white light is acceptable for periods not exceeding 4 hours, beyond which the vessel is wrapped with amber film to prevent photodegradation. Automated synthesizer feed lines are equilibrated with dry DMF for 30 minutes before monomer addition, and the monomer solution is prepared at 0.2 M concentration in DMF containing 0.1 M hydroxybenzotriazole to stabilize the activated carboxylate during coupling cycles.

The Carboxyl Terminus Is Activated as a Succinimidyl Ester for Polymer-Drug Conjugation

For polymer-drug conjugation, the carboxyl terminus of Fmoc-L-phenylalanine is converted to an N-hydroxysuccinimide ester for covalent attachment to amine-terminated poly(ethylene glycol), amine-grafted poly(lactic-co-glycolic acid), or amino-functionalized dendrimers. In a representative activation, 1.0 equivalent of Fmoc-Phe-OH is dissolved in anhydrous acetonitrile at 25°C, 1.1 equivalents of N,N′-disuccinimidyl carbonate are added, and 0.1 equivalents of 4-dimethylaminopyridine are used as acylation catalyst; the reaction proceeds for 18 hours under nitrogen. The activated Fmoc-Phe-OSu is isolated by precipitation in cold diisopropyl ether or from acetonitrile/water, then dried under vacuum at 25°C to residual water below 0.5% by Karl Fischer titration according to USP <921>. Conjugation to amine-terminated poly(ethylene glycol) of molecular weight 2,000–10,000 Da is carried out in anhydrous dichloromethane or acetonitrile with 1.2 equivalents of Fmoc-Phe-OSu and 2.0 equivalents of N,N-diisopropylethylamine; the reaction is monitored by reverse-phase HPLC according to USP <621> until free polymer amine is below 1.0 area%. Unreacted Fmoc-Phe-OH and its succinimidyl ester are removed by dialysis against acetonitrile followed by water, or by precipitation in cold ethyl ether. The Fmoc group on the polymer-bound phenylalanine is cleaved with 20% v/v piperidine in DMF for 10 minutes to expose the primary amine for subsequent peptide chain extension or fluorophore attachment; the released dibenzofulvene is removed by repeated precipitation. Batch release criteria for the polymer conjugate include acylated amine content above 95 mol%, free Fmoc-Phe-OH below 0.1 area% by HPLC, and residual N,N′-dicyclohexylurea or dicyclohexylcarbodiimide controlled when the alternative DCC/NHS route is used. Compliance for pharmaceutical development is based on ICH Q3C for residual acetonitrile, dichloromethane, and methyl tert-butyl ether, USP <467> for solvent residues, and ICH Q3D for tin, palladium, and cobalt when metallic catalysts are introduced in polymer synthesis. Final products are Fmoc-Phe-functionalized poly(ethylene glycol) block copolymers, PLGA conjugates, and dendrimer intermediates intended for nanoparticle formulation, controlled release, and surface modification of biodegradable implants; the material is stored at −20°C under argon after lyophilization to minimize ester hydrolysis and Fmoc cleavage.